Dual effect of apolipoprotein(a) on plasmin(ogen)-induced apoptosis through modulation of cell detachment of adherent cells

Thrombosis and Haemostasis

Volumn 95, Issue 1, 2006, Pages 142-150

  Ho Tin Noé, Benoît ^a,b   Meilhac, Olivier ^a,b   Rossignol, Patrick ^a,b   Lijnen, H Roger ^c   Anglés Cano, Eduardo ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Apolipoprotein(a); Cell detachment induced apoptosis; CHO KI cells; Plasminogen; Vascular smooth muscle cells

Indexed keywords

APOLIPOPROTEIN A; LEUKOCYTE ELASTASE; PLASMINOGEN; TRYPSIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BINDING AFFINITY; CELL ADHESION; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SMOOTH MUSCLE FIBER; STRUCTURAL HOMOLOGY; THROMBOGENESIS; THROMBOSIS; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA; APOLIPOPROTEINS A; APOPTOSIS; BINDING, COMPETITIVE; CELL ADHESION; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; KINETICS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PLASMIN; PLASMINOGEN; RATS; RATS, WISTAR; RECOMBINANT PROTEINS;

EID: 33645537626     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-07-0505     Document Type: Article

References (48)

1. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102: 1082-5.
2. Eaton DL, Fless GM, Kohr WJ et al. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci U S A 1987; 84: 3224-8.
3. McLean JW, Tomlinson JE, Kuang WJ et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330: 132-7.
4. Ernst A, Helmhold M, Brunner C et al. Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). J Biol Chem 1995; 270: 6227-34.
5. Hervio L, Durlach V, Girard-Globa A et al, Multiple binding with identical linkage: a mechanism that explains the effect of lipoprotein(a) on fibrinolysis. Biochemistry 1995; 34: 13353-8.
6. Rouy D, Grailhe P, Nigon F et al. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu. Arterioscler Thromb 1991; 11: 629-38.
7. Miles LA, Fless GM, Levin EG et al. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989; 339: 301-3.
8. Hajjar KA, Gavish D, Breslow JL et al. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989; 339: 303-5.
9. Boonmark NW, Lou XJ, Yang ZJ et al. Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. J Clin Invest 1997; 100: 558-64.
10. Soulat T, Loyau S, Baudouin V et al. Evidence that modifications of Lp(a) in vivo inhibit plasmin formation on fibrin--a study with individual plasmas presenting natural variations of Lp(a). Thromb Haemost 1999; 82: 121-7.
11. Kronenberg F, Kronenberg ME, Kiechl S et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 1999; 100: 1154-60.
12. Pepin JM, O'Neil JA, Hoff HF. Quantification of apo[a] and apoB in human atherosclerotic lesions. J Lipid Res 1991; 32: 317-27.
13. Rath M, Niendorf A, Reblin T et al. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989; 9: 579-92.
14. Zambrelli E, Emanuele E, Marcheselli S et al. Apo(a) size in ischemic stroke: relation with subtype and severity on hospital admission. Neurology 2005; 64: 1366-70.
15. Longenecker JC, Klag MJ, Marcovina SM et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol 2005; 16: 1794-802.
16. Bot I, von der Thusen JH, Donners MM et al. Serine protease inhibitor Serp-1 strongly impairs atherosclerotic lesion formation and induces a stable plaque phenotype in ApoE-/-mice. Circ Res 2003; 93: 464-71.
17. Meilhac O, Ho-Tin-Noe B, Houard X et al. Pericellular plasmin induces smooth muscle cell anoikis. FASEB J 2003; 17: 1301-1303.
18. Reijerkerk A, Mosnier LO, Kranenburg O et al. Amyloid endostatin induces endothelial cell detachment by stimulation of the plasminogen activation system. Mol Cancer Res 2003; 1: 561-8.
19. Rossignol P, Ho-Tin-Noe B, Vranckx R et al. Protease-nexin-1 inhibits plasminogen activation-induced apoptosis of adherent cells. J Biol Chem 2004; 279: 10346-56.
20. Ho-Tin-Noe B, Rojas G, Vranckx R et al. Functional hierarchy of plasminogen kringles 1 and 4 in fibrinolysis and plasmin-induced cell detachment and apoptosis. Febs J 2005; 272: 3387-400.
21. Syrovets T, Thillet J, Chapman MJ et al. Lipoprotein(a) is a potent chemoatttactant for human peripheral monocytes. Blood 1997; 90: 2027-36.
22. Galle J, Schneider R, Heinloth A et al. Lp(a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: role of oxidative stress. Kidney Int 1999; 55: 1450-61.
23. Ichikawa T, Unoki H, Sun H et al. Lipoprotein(a) promotes smooth muscle cell proliferation and dedifferentiation in atherosclerotic lesions of human apo(a) transgenic rabbits. Am J Pathol 2002; 160: 227-36.
24. Kim JS, Chang JH, Yu HK et al. Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a). J Biol Chem 2003; 278: 29000-8.
25. Pellegrino M, Furmaniak-Kazmierczak E, LeBlanc JC et al. The apolipoprotein(a) component of lipoprotein(a) stimulates actin stress fiber formation and loss of cell-cell contact in cultured endothelial cells. J Biol Chem 2004; 279: 6526-33.
26. Battle T, Arnal JF, Challah M et al. Selective isolation of rat aortic wall layers and their cell types in culture--application to converting enzyme activity measurement. Tissue Cell 1994; 26: 943-55.
27. Fleury V, Lijnen HR, Angles-Cano E. Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis. J Biol Chem 1993; 268: 18554-9.
28. Wiman B, Wallen P. Activation of human plasminogen by an insoluble derivative of urokinase. Structural changes of plasminogen in the course of activation to plasmin and demonstration of a possible intermediate compound. Eur J Biochem 1973; 36: 25-31.
29. Angles-Cano E, Loyau S, Cardoso-Saldana G et al. A novel kringle-4 number-based recombinant apo[a] standard for human apo[a] phenotyping. J Lipid Res 1999; 40: 354-9.
30. Tsurupa G, Ho-Tin-Noe B, Angles-Cano E et al. Identification and characterization of novel lysine-independent apolipoprotein(a)-binding sites in fibrin (ogen) alphaC-domains. J Biol Chem 2003; 278: 37154-9.
31. Montes R, Paramo JA, Angles-Cano E et al. Development and clinical application of a new ELISA assay to determine plasmin-alpha2-antiplasmin complexes in plasma. Br J Haematol 1996; 92: 979-85.
32. Adamson AW. Physical Chemistry of Surfaces. New York: Wiley-Interscience Publication; 1992,
33. Kang C, Durlach V, Soulat T et al. Lipoprotein(a) isoforms display differences in affinity for plasminogen-like binding to human mononuclear cells. Arterioscler Thromb Vasc Biol 1997; 17: 2036-43.
34. Plow EF, Herren T, Redlitz A et al. The cell biology of the plasminogen system. Faseb J 1995; 9: 939-45.
35. Lupu F, Heim DA, Bachmann F et al. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995; 15: 1444-55.
36. Clowes AW, Clowes MM, Au YP et al. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 1990; 67: 61-7.
37. Rickard KA, Taylor J, Rennard SI. Observations of development of resistance to detachment of cultured bovine bronchial epithelial cells in response to protease treatment. Am J Respir Cell Mol Biol 1992; 6: 414-20.
38. Mtairag el M, Houard X, Rais S et al. Pharmacological potentiation of natriuretic peptide limits polymorphonuclear neutrophil-vascular cell interactions. Arterioscler Thromb Vasc Biol 2002; 22: 1824-31.
39. van der Hoek YY, Sangrar W, Cote GP et al. Binding of recombinant apolipoprotein(a) to extracellular matrix proteins. Arterioscler Thromb 1994; 14: 1792-8.
40. Bihari-Varga M, Gruber E, Rotheneder M et al. Interaction of lipoprotein Lp(a) and low density lipoprotein with glycosaminoglycans from human aorta. Arteriosclerosis 1988; 8: 851-7.
41. Auerbach BJ, Cain W, Ansong M et al. Lipoprotein lipase greatly enhances the retention of lipoprotein(a) to endothelial cell-matrix. Arterosclerosis 1999; 142: 89-96.
42. Klezovitch O, Edelstein C, Zhu L et al. Apolipoprotein(a) binds via its C-terminal domain to the protein core of the proteoglycan decorin. Implications for the retention of lipoprotein(a) in atherosclerotic lesions. J Biol Chem 1998; 273: 23856-65.
43. D'Angelo A, Geroldi D, Hancock MA et al. The apolipoprotein(a) component of lipoprotein(a) mediates binding to laminin: contribution to selective retention of lipoprotein(a) in atherosclerotic lesions. Biochim Biophys Acta 2005; 1687: 1-10.
44. Bdeir K, Cane W, Canziani G et al. Defensin promotes the binding of lipoprotein(a) to vascular matrix. Blood 1999; 94: 2007-19.
45. Caird J, Burke M, Roberts G et al. Apolipoprotein(A) expression in intracranial aneurysms. Neurosurgery 2003; 52: 854-8; discussion 858-9.
46. Papagrigorakis E, Iliopoulos D, Asimacopoulos PJ et al. Lipoprotein(a) in plasma, arterial wall, and thrombus from patients with aortic aneurysm. Clin Genet 1997; 52: 262-71.
47. Cushing GL, Gaubatz JW, Nava ML et al. Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis 1989; 9: 593-603.
48. Fontaine V, Jacob MP, Houard X et al. Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms. Am J Pathol 2002; 161: 1701-10.